Meds Pages » Articles

General Practice Training – What Lies Ahead? Australia

admin — Mon, 06 Jun 2011 18:33:36 +0000

A supplement in the latest Medical Journal of Australia examines the past and the future for general practice training, including challenges in areas such as keeping training programs upto- date, Indigenous health, rural and remote health, aged care and military medicine. Professor Michael Kidd from Flinders University and co-editors of the supplement examine the past experiences, the contemporary issues and what lies ahead for general practice training. Prof Kidd said that there were many challenges for general practice in the years ahead… (Source: Health News from Medical News Today)

Further information:

Article source

Landmark Breast Cancer Prevention Trial Finds Exemestane Significantly Reduces Risk Of Breast Cancer, Canada

admin — Mon, 06 Jun 2011 18:33:34 +0000

A large international Canadian-led clinical trial investigating a new way to prevent breast cancer in women at increased risk of developing the disease has found that the drug exemestane reduces this risk by 65 per cent compared with placebo. The results were presented today at the annual meeting of the American Society of Clinical Oncology and published online by the New England Journal of Medicine. With funding from the Canadian Cancer Society, the NCIC Clinical Trials Group (CTG) led the trial which tested the drug exemestane, a member of a class of drugs called aromatase inhibitors… (Source: Health News from Medical News Today)

Further information:

Article source

7 Dirt-Cheap Takeover Targets in Biotech

admin — Mon, 06 Jun 2011 18:33:17 +0000

Rougemont submits:

Biotechs and healthcare stocks have been outperfoming the market. These dirt-cheap biotech companies all have interesting products in the pipeline that could become major catalysts in the future. The lower-priced stocks tend to have more risk, but far more potential reward. The stocks below are trading at valuations that appear to be a buying opportunity that could provide for very substantial gains. Many of these stocks fell from their long term highs, on analyst downgrades and other issues. Others have been seemingly ignored by the stock market and do not appear to be fully valued. There is nothing better than buying a stock at a very low price and watching it become worth several times your initial investment. Some of these stocks have spiked up lately — names like Inhibitex (INHX), Acorda (ACOR), and Biosante (BPAX) — so I would wait for pullbacks. However, others like Catalyst Pharmaceutical Partners (CPRX)

Complete Story »

Further information:

Article source

Estimates of Outcomes Up to Ten Years after Stroke: Analysis from the Prospective South London Stroke Register

admin — Mon, 06 Jun 2011 18:33:16 +0000

by Charles D. A. Wolfe, Siobhan L. Crichton, Peter U. Heuschmann, Christopher J. McKevitt, André M. Toschke, Andy P. Grieve, Anthony G. Rudd

Background

Although stroke is acknowledged as a long-term condition, population
estimates of outcomes longer term are lacking. Such estimates would be
useful for planning health services and developing research that might
ultimately improve outcomes. This burden of disease study provides
population-based estimates of outcomes with a focus on disability,
cognition, and psychological outcomes up to 10 y after initial stroke event
in a multi-ethnic European population.

Methods and Findings

Data were collected from the population-based South London Stroke Register, a
prospective population-based register documenting all first in a lifetime
strokes since 1 January 1995 in a multi-ethnic inner city population. The
outcomes assessed are reported as estimates of need and included disability
(Barthel Index <15), inactivity (Frenchay Activities Index <15),
cognitive impairment (Abbreviated Mental Test < 8 or Mini-Mental State
Exam <24), anxiety and depression (Hospital Anxiety and Depression Scale
>10), and mental and physical domain scores of the Medical Outcomes Study
12-item short form (SF-12) health survey. Estimates were stratified by age,
gender, and ethnicity, and age-adjusted using the standard European
population. Plots of outcome estimates over time were constructed to examine
temporal trends and sociodemographic differences. Between 1995 and 2006,
3,373 first-ever strokes were registered: 20%–30% of
survivors had a poor outcome over 10 y of follow-up. The highest rate of
disability was observed 7 d after stroke and remained at around 110 per
1,000 stroke survivors from 3 mo to 10 y. Rates of inactivity and cognitive
impairment both declined up to 1 y (280/1,000 and 180/1,000 survivors,
respectively); thereafter rates of inactivity remained stable till year
eight, then increased, whereas rates of cognitive impairment fluctuated till
year eight, then increased. Anxiety and depression showed some fluctuation
over time, with a rate of 350 and 310 per 1,000 stroke survivors,
respectively. SF-12 scores showed little variation from 3 mo to 10 y after
stroke. Inactivity was higher in males at all time points, and in white
compared to black stroke survivors, although black survivors reported better
outcomes in the SF-12 physical domain. No other major differences were
observed by gender or ethnicity. Increased age was associated with higher
rates of disability, inactivity, and cognitive impairment.

Conclusions

Between 20% and 30% of stroke survivors have a poor range of
outcomes up to 10 y after stroke. Such epidemiological data demonstrate the
sociodemographic groups that are most affected longer term and should be
used to develop longer term management strategies that reduce the
significant poor outcomes of this group, for whom effective interventions
are currently elusive.

Please see later in the article for the Editors’ Summary

Further information:

Article source

New Strain of MRSA Found in Milk

admin — Mon, 06 Jun 2011 18:33:15 +0000

Title: New Strain of MRSA Found in Milk
Category: Health News
Created: 6/3/2011 11:00:00 AM
Last Editorial Review: 6/3/2011

Further information:

Article source

Molecular expression profiling with respect to KEGG hsa05219 pathway

admin — Mon, 06 Jun 2011 18:33:14 +0000

One of the most promising avenues for interpreting large datasets of molecular expression profiles involves pathway-based analysis. Pathways are collection of genes and proteins that perform a well-defined biological task. These pathways have been established through decades of molecular biology research and are collected in a variety of public pathway repositories (KEGG and Reactome Pathway database). Understanding the complexity of these pathways is critical for understanding normal biological conditions and disease states and also since the number of known pathways within the cells is significantly smaller than the number of genes that is typically profiled, the transformation of data from a gene-centric view to a pathway-centred one represents a dramatic reduction in the number of dimensions. Such reduction allows a biologist to interpret and understand the data in a manner that is not possible when it is viewed as a collection of individual genes.

Further information:

Article source

Flu jab may cut early birth risk

admin — Mon, 06 Jun 2011 18:33:11 +0000

Influenza vaccination could protect unborn children from the risk of premature birth, a study suggests.

Further information:

Article source

Axiomtek’s SBC84826 3.5in Embedded Board Supports -40°C to +85°C Temperature Range

admin — Mon, 06 Jun 2011 18:33:08 +0000

Axiomtek has announced its wide-temperature SBC84826 3.5in embedded board for solutions used in unconstrained thermal environments like outdoor embedded system, medical, industrial control, automation, and gaming machines. The rugged yet super-compact size SBC84826 supports an industrial-temperature grade Intel® Atom™ processor Z510PT 1.1GHz with the Intel System Controller Hub (SCH) US15WPT. It offers -40°C to +85°C wide temperature range and only requires +12V DC power input. One DDR2 SODIMM on board implements up to 2GB of system memory. The onboard Intel SCH US1…

Read More

Post to:

Delicious

Further information:

29 New Products Now Available from Bachem

admin — Mon, 06 Jun 2011 18:33:06 +0000

Bachem is continuously expanding and updating its extensive range of products for your research purposes. We are pleased to present our latest product additions, which include several Pro-VGF-derived peptides, osteoblast activating peptides, and two deuterium-labelled API analogs. A number of products including building blocks for click chemistry and new coupling reagents has also been added to our offer of amino acid derivatives.
Today’s release of 29 new products includes:
Pro-VGF-derived peptides
AQEE-30 and LQEQ-19 have been described to induce penile erection when injected into the pa…

Read More

Post to:

Delicious

Further information:

Lower Doses Of Anti-Gout Drug Recommended

admin — Mon, 06 Jun 2011 18:33:01 +0000

Health professionals should ensure they are prescribing correct doses of colchicine, a treatment for acute gout, after three elderly patients were hospitalised within a fortnight, doctors at St Vincent’s Hospital in Sydney say in a letter published in the Medical Journal of Australia. All three patients presented with vomiting and diarrhoea, and all had been taking higher than recommended doses of colchicine, wrote the authors, from the Department of Clinical Pharmacology and Toxicology at St Vincent’s… (Source: Health News from Medical News Today)

Further information:

Article source